Estimation of the correlation of the level of blood heparan sulphate and clinical and morphological manifestations of chronic glomerulonephritis


DOI: https://dx.doi.org/10.18565/therapy.2019.3.79-85

Bayandurova K.M., Batyushin M.M., Sarvilina I.V., Antipova N.V., Sinelnik E.A.

1) Department of internal diseases No. 2 of Rostov State medical University of the Ministry of Healthcare of Russia; 2) Medical center «Novomedicina»; 3) Rostov clinical regional hospital No 2 of Rostov region
The purpose of the study is to determine the relationship between the level of heparan sulfate in the serum of patients with various forms of chronic glomerulonephritis with various morphological manifestations in the renal tissue.
Material and methods. A detailed clinical and laboratory examination of 80 CGN patients in the acute stage was carried out It included the determination of serum heparan sulfate by enzyme immunoassay method and the performance of renal biopsy puncture with morphological changes estimation.
Results and conclusion. The data obtained in the study demonstrate the important role of heparan sulfate in the process of remodeling of tubulointerstitium, confirm its role as a marker of kidney damage, to a greater extent in IgA nephropathy and nephritic syndrome. The studied indicator could be considered to be as a marker of tubulointerstitial fibrosis, and also reflects the severity of the activity of the inflammatory process. Determining the level of heparan sulfate in the blood serum can be an informative non-invasive method, allowing to evaluate the disease activity and prognosis of the course of chronic glomerulonephritis.
Keywords: proteoglycans, heparan sulphate, chronic renal failure, chronic glomerulonephritis
Read entire article

Literature


  1. Jha V., Garcia-Garcia G., Iseki K. et al. Chronic kidney disease:global dimension and perspectives. Lancet. 2013; 382: 260–72.

  2. Taylor D.M.A., Fraser S.D.S., Bradley J.A. et al. Systematic review of the prevalence and associations of limited health literacy in CKD. Clin. J. Am. Soc. Nephrol. 2017; 12(7): 1070–84.

  3. United States Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2013.

  4. Caliskan Y., Kiryluk K. Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis. 2014; 21(2): 205–16.

  5. Rienstra H., Katta K., Celie J.W. et al. Differential expression of proteoglycans in tissue remodeling and lymphangiogenesis after experimental renal transplantation in rats. PLoS One. 2010; 5(2): e9095.

  6. Mallamaci F. Highlights of the 2015 ERA-EDTA congress: chronic kidney disease, hypertension. Nephrol Dial Transplant. 2016; 31(7): 1044–46. doi: 10.1093/ndt/gfw006. Epub 2016 Feb 29.

  7. Neprasova M., Maixnerova D., Novak J., Reily C., Julian B.A., Boron J., Novotny P., Suchanek M., Tesar V., Kacer P. Toward noninvasive diagnosis of IgA nephropathy: a pilot urinary metabolomic and proteomic study. Dis Markers. 2016; 2016: 3650909. Epub 2016 Oct 9.

  8. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115(10): 1285–95.

  9. Celie J.W., Reijmers R.M., Slot E.M., Beelen R.H., Spaargaren M., Ter Wee P.M., Florquin S., van den Born J. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol Renal Physiol. 2008; 294(1): F253–63. Epub 2007 Nov 21.

  10. Chen J., Hamm L.L., Mohler E.R. et al. Interrelationship of Multiple Endothelial Dysfunction Biomarkers with Chronic Kidney Disease. PLoS One. 2015; 10(7): e0132047. doi: 10.1371/journal.pone.0132047.

  11. Ebefors K., Granqvist A., Ingelsten M. et al. Role of glomerular proteoglycans in IgA nephropathy. PLoS One. 2011; 6(4): e18575. doi: 10.1371/journal.pone.0018575.


About the Autors

Karina M. Bayandurova, junior doctor of the Department of internal diseases No. 2, Rostov State medical University of the Ministry of Healthcare of Russia. Address: 344022 Rostov-on-Don, 29 Nakhichevansky Lane. Tel.: +7 (988) 257-76-67. E-mail: karina1611994@gmal.com
Mikhail M. Batyushin, MD, professor of the Department of internal medicine No 2 of Rostov State medical University of the Ministry of Healthcare of Russia. Address: 344014, Rostov-on-Don, 29 Nakhichevansky Lane. Tel.: +7 (863) 201-44-23. E-mail: batjushin-m@rambler.ru
Irina V. Sarvilina, MD, professor, clinical pharmacologist, chief physician of «Novomedicina» medical Center. Address: 344022, Russia, Rostov-on-Don, 74 Sotsialisticheskaya Str. Business Center «Kupechesky Dvor», office 1030. Tel.: +7 (903) 436-48-66. E-mail: isarvilina@mail.ru
Elena A. Sinelnik, Doctor of the highest qualification category, Head of prosectorium Department of Rostov regional clinical hospital No. 2. Address: 344022, Rostov-on-Don, 3 Pervoi Konnoi Armii Str. Tel.: +7 (863) 252-19-30. E-mail: ob2p@mail.ru
Natalia V. Antipova, high level certificate physician, Head of the nephrological Department of Rostov regional clinical hospital No.2. Address: 344022, Rostov-on-Don, 3 Pervoi Konnoi Armii Str. Tel.: +7 (918) 553-65-22. E-mail: ob2p@mail.ru


Similar Articles

Back to Content

Бионика Медиа